<DOC>
	<DOCNO>NCT02227823</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy anti-cholinesterase therapy motor function SMA type 3 patient impaired neuromuscular junction ( NMJ ) .</brief_summary>
	<brief_title>Safety Efficacy Study Pyridostigmine Patients With Spinal Muscular Atrophy Type 3</brief_title>
	<detailed_description>Spinal muscular atrophy ( SMA ) second neuromuscular disease meet child . SMA genetically transmit disease induce muscular weakness predominate shoulder hip . Currently , effective therapy slow progression disease . SMA due neuron motor attempt spinal cord recently demonstrate neuromuscular junction ( NMJ ) involvement , accord recent study . EMOTAS study aim understand NMJ abnormality could impact motor performance fatigue SMA type 3 ambulatory patient electromyogram improve non-invasive therapy quality life patient .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Spinal Muscular Atrophies Childhood</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Pyridostigmine Bromide</mesh_term>
	<criteria>Spinal muscular atrophy type 3 , genetically confirm Age high 6 year old Ambulatory patient Informed consent sign More 100 meter walk 6minute walk test screen Value screen baseline range 20 % high value 6minute walk test Patient surgical intervention suffer recent traumatism ( le 6 month ) Associated pathology endocrinopathy , infectious disease , allergy , myopathy , chronic acute inflammatory pathology , 3 week precede inclusion . Other therapeutic food supplement frequently prescribe spinal muscular atrophy complication Non tolerance electromyography Limited collaboration due trouble information comprehension Pathology induce contraindication pyridostigmine treatment ( allergy molecule , asthma , Parkinson disease , mechanic obstruction urinary digestive tract )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>spinal muscular atrophy type 3</keyword>
	<keyword>electromyography</keyword>
	<keyword>fatigability</keyword>
	<keyword>decrement</keyword>
</DOC>